Remove Biomarkers Remove Cardiovascular Disease Remove Cholesterol
article thumbnail

Remnant cholesterol, lipid ratios, and the severity of coronary artery lesions: a retrospective cohort study in patients with coronary heart disease

Frontiers in Cardiovascular Medicine

BackgroundEmerging genetic and observational evidence indicates that remnant cholesterol (RC) is a significant residual risk factor for cardiovascular diseases. However, there is a relative paucity of evidence exploring the correlation among RC, lipid ratios, and atherosclerotic lesion severity.

article thumbnail

New study shows glycan sugar coating of IgG immunoglobulin can predict cardiovascular health

Medical Xpress - Cardiology

When people hear about predicting heart disease, most will think of cholesterol levels.

article thumbnail

Cholesterol Crystal Dissolution Rate of Serum Predicts Outcomes in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Journal of the American Heart Association

BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. The resulting cholesterol crystals activate the NLRP3 (NOD‐like receptor protein 3) inflammasome, leading to inflammation and cardiovascular diseases. mg/dL versus 97.9±37.6

article thumbnail

Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation

Frontiers in Cardiovascular Medicine

For many disease areas, nearly a half of drugs are approved by the U.S. For cardiovascular disease, only low-density lipoprotein cholesterol and blood pressure are approved as surrogates for cardiovascular disease. Food & Drug Administration based on beneficial effects on surrogate endpoints.

Plaque 59
article thumbnail

Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer

Heart BMJ

This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovascular disease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. years (range 5.9–10.8

Cancer 52
article thumbnail

APOE4 & Cardiovascular Risk

Dr. Paddy Barrett

However Most people do not appreciate that being a carrier of APOE4 significantly increases the risk of cardiovascular disease also. APO E is also centrally involved in cholesterol metabolism. APO E is also centrally involved in cholesterol metabolism. i.e. LDL-Cholesterol/APOB goes down. Here’s how.

article thumbnail

Do Statins Cause Dementia?

Dr. Paddy Barrett

I do apologise for being direct, but this issue is one of the most frequent barriers I encounter to initiating cholesterol-lowering therapy. At the exact same time, cholesterol concentrations are also at their lowest. At the exact same time, cholesterol concentrations are also at their lowest. Let’s break this down.